Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus

MILWAUKEE, May 3, 2023 /PRNewswire/ -- Ademi LLP is investigating Magenta (Nasdaq: MGTA) for possible breaches of fiduciary duty and other violations of law in its transaction with Dianthus. 

Click here to learn how to join the action https://www.ademilaw.com/case/magenta-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

Magenta stockholders are expected to own only approximately 21.3% of the combined company. The percentage of the combined company that Magenta's stockholders will own is subject to adjustment based on the amount of Magenta's net cash at closing. Immediately prior to the proposed merger, Magenta stockholders will be issued contingent value rights representing the right to receive certain payments from proceeds received by the combined company, if any, related to pre-transaction legacy assets. The transaction agreement unreasonably limits competing bids for Magenta by imposing a significant penalty if Magenta accepts a superior bid. Magenta insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Magenta's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Magenta.

If you own Magenta common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/magenta-therapeutics-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                                                       
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP